BioForm targets $115m IPO (initial public offering) for product push:
This article was originally published in Clinica
Executive Summary
Plastic surgery specialist BioForm Medical has filed for an initial public offering that could boost funds by $115m. The firm is looking to finance the development of its Radiesse injectable dermal filler, which received FDA pre-market approvals in December 2006 for the treatment of facial lipoatrophy - facial fat loss - in patients with HIV and for cosmetic correction of wrinkles. The San Mateo, California-based company will also use a portion of the offering proceeds to gain US regulatory approval of its varicose vein treatment Aethoxysklerol (currently in Phase III clinical trials in the US) and BioGlue, a surgical adhesive for use in browplasty, which is in early-stage human trials. BioForm holds exclusive US distribution rights to Aethoxysklerol and exclusive US and Canadian distribution rights to BioGlue for medical aesthetic applications.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.